A 10-year hospital study reveals how often prediabetes progresses to type 2 diabetes—and how early intervention can reverse ...

Patients who discontinued tirzepatide during the 17-week off-treatment period began to regain weight. Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with ...

Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.

New research (the Ver-A-T1D trial) presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...